J.D., Chief Executive Officer, Good Start Genetics, Inc.
Mr. Luber is President and CEO of Good Start Genetics, Inc., a national provider of high quality, affordable genetic sequencing for families from preconception through early childhood. With more than twenty years of experience bringing new healthcare products to market, Mr. Luber has served in leadership roles at the nexus of discovery and commercial rollout. In 2009, Mr. Luber co-founded SynapDx Corp, focused on the development of the first blood-based test for the early detection of autism. Prior to SynapDx, Mr. Luber served as CEO of EXACT Sciences Corp (NASDAQ: EXAS), where he orchestrated key foundational partnerships, helped win inclusion in the medical screening guidelines of the American Cancer Society and America College of Gastroenterology, and restored the company to long-term health through a strategic transaction with Genzyme Corp. He received his BS in Business Administration from Southern Connecticut State University and his JD and MBA from Suffolk University.
Preconception Precision Testing: An Ounce of Prevention
Inherited disorders account for an estimated 10% of infant mortality and 20% of pediatric hospitalizations. Families who live with common inherited disorders suffer for many years. Affordable next generation sequencing can bring genetics into the mainstream and profoundly affect health outcomes globally through better preconception testing and unique delivery models.